中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

3718 records (took 0.071 seconds)

    SOLID PREPARATION
    333.
    发明申请
    SOLID PREPARATION 审中-公开
    固体制剂

    公开(公告)号：WO2012133918A1

    公开(公告)日：2012-10-04

    申请号：PCT/JP2012/059276

    申请日：2012-03-29

    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  HOSHINA, Wataru ,  MISAKI, Masafumi

    Inventor： HOSHINA, Wataru ,  MISAKI, Masafumi

    IPC: A61K9/20 ,  A61K31/4188

    CPC classification number: A61K9/2009 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/28 ,  A61K31/4188 ,  A61K47/02

    Abstract: The present invention provides a solid preparation wherein variation in weight is suppressed, a solid preparation wherein the active ingredient is stabilized, and a stabilization method thereof. A solid preparation containing (1) an active ingredient, (2) D-mannitol and (3) an alkaline earth metal salt selected from magnesium aluminometasilicate and calcium silicate. A method of stabilizing the. active ingredient, including adding an alkaline earth metal salt selected from magnesium aluminometasilicate and calcium silicate.

    Abstract translation: 本发明提供了其中抑制重量变化的固体制剂，其中活性成分稳定的固体制剂及其稳定化方法。 一种固体制剂，其含有（1）活性成分，（2）D-甘露糖醇和（3）选自硅铝酸镁和硅酸钙的碱土金属盐。 一种稳定的方法。 包括加入选自硅酸铝镁和硅酸钙的碱土金属盐。

    ORALLY DISINTEGRATING TABLET
    335.
    发明申请
    ORALLY DISINTEGRATING TABLET 审中-公开
    ORIALY DISINTEGRATING TABLET

    公开(公告)号：WO2012091153A2

    公开(公告)日：2012-07-05

    申请号：PCT/JP2011/080568

    申请日：2011-12-26

    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  ISHII, Shiro ,  EBISAWA, Yutaka ,  OKABE, Takayuki

    Inventor： ISHII, Shiro ,  EBISAWA, Yutaka ,  OKABE, Takayuki

    IPC: A61K9/00

    CPC classification number: A61K9/2081 ,  A61K9/0056 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/5015 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5078 ,  A61K31/4439

    Abstract: Provided is an orally disintegrating tablet obtained by tableting fine granules showing controlled release of lansoprazole and an additive, which is capable of suppressing breakage of the fine granules during tableting, and can control the release of lansoprazole for a long time, and can maintain a therapeutically effective concentration for a prolonged time, and shows superior disintegration property in the oral cavity. An orally disintegrating tablet containing (i) fine granules showing controlled release of a pharmaceutically active ingredient, which contains fine granules containing a pharmaceutically active ingredient and a coating layer containing a methacrylic acid/methyl acrylate/methyl methacrylate copolymer, wherein the fine granules containing a pharmaceutically active ingredient are coated with more than 80 wt% and not more than 300 wt% of the copolymer, and (ii) fine granules showing controlled release of a pharmaceutically active ingredient, which contains the pharmaceutically active ingredient and a coating layer comprising (a) an ethyl acrylate/methyl methacrylate copolymer, and (b) one or more kinds of polymers selected from the group consisting of methacrylic acid/ethyl acrylate copolymer, hypromellose phthalate, carboxymethylethylcellulose, polyvinyl acetate phthalate, hydroxypropyl methylcellulose acetate succinate and cellulose acetate phthalate, wherein the fine granules (i) and fine granules (ii) have an average particle size of not more than 500 micrometer, and the pharmaceutically active ingredient is lansoprazole or an optically active form thereof or a salt thereof.

    Abstract translation: 本发明提供了一种口腔崩解片剂，其通过将显示出控制释放的兰索拉唑和添加剂的微粒压片，所述压片能够抑制压片过程中细粒的破裂，并且可以控制兰索拉唑释放 时间长，并且可以长时间维持治疗有效浓度，并且在口腔中表现出优异的崩解性质。 一种口腔崩解片剂，其中含有（ⅰ）显示药物活性成分受控释放的细粒，其含有含有药物活性成分的细粒和含有甲基丙烯酸/丙烯酸甲酯/甲基丙烯酸甲酯共​​聚物的包衣层，其中含有 药物活性成分用超过80重量％且不超过300重量％的共聚物包衣，和（ii）显示药物活性成分受控释放的细颗粒，其含有药物活性成分和包含（a ）丙烯酸乙酯/甲基丙烯酸甲酯共​​聚物，和（b）选自甲基丙烯酸/丙烯酸乙酯共聚物，羟丙甲纤维素邻苯二甲酸酯，羧甲基乙基纤维素，聚乙酸乙烯邻苯二甲酸酯，乙酸琥珀酸羟丙基甲基纤维素和乙酸邻苯二甲酸纤维素的一种或多种聚合物， 其中细颗粒（i）和f （ii）的颗粒具有不超过500微米的平均粒径，并且药物活性成分是兰索拉唑或其旋光形式或其盐。

    THERAPEUTIC AGENT FOR BRAIN TUMOR
    339.
    发明申请
    THERAPEUTIC AGENT FOR BRAIN TUMOR 审中-公开
    脑肿瘤治疗剂

    公开(公告)号：WO2011040212A1

    公开(公告)日：2011-04-07

    申请号：PCT/JP2010/065674

    申请日：2010-09-06

    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  OHTA, Yoshikazu ,  TAMURA, Toshiya

    Inventor： OHTA, Yoshikazu ,  TAMURA, Toshiya

    IPC: A61K31/519 ,  A61P35/00 ,  A61P35/04

    CPC classification number: A61K31/519

    Abstract: The present invention relates to an agent for the prophylaxis or treatment of metastatic tumor that has spread to the brain from other tissue, comprising N-{2-[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-3-hydroxy-3-methylbutanamide or a salt thereof.

    Abstract translation: 本发明涉及用于预防或治疗已经从其他组织扩散至脑的转移性肿瘤的试剂，其包含N- {2- [4 - （{3-氯-4- [3-（三氟甲基）苯氧基] 苯基}氨基）-5H-吡咯并[3,2-d]嘧啶-5-基]乙基} -3-羟基-3-甲基丁酰胺或其盐。

Patent Agency Ranking